Female condoms

Gus Cairns

The most effective method to prevent HIV acquisition and transmission, the condom, is worn by men. Many women do not have relationships of equality with the men they have sex with, and they can experience difficulties persuading men to use condoms. This can be particularly difficult in situations where possible HIV transmission is not a woman’s primary concern (for example, when the woman experiences violence). However, it is also problematic for women in more equal relationships, since many men find condoms difficult to use or dislike them, and as men are less vulnerable to HIV than women from vaginal intercourse, they may not afford the same priority to condom use.

When it was introduced in 1993, at the height of the AIDS crisis in the developed world, the world’s first female condom, the Femidom, was hailed as the first female-controlled barrier method for preventing HIV, sexually transmitted infections (STIs) and pregnancy. It was forecast that it could make a significant contribution to HIV prevention.

Over fifteen years later, this, the only new prevention technology invented and approved since the advent of the HIV epidemic, has yet to fulfil its promise. Although there are significant female-condom distribution and education programmes in a number of developing countries, including South Africa and Brazil, its use has largely remained confined to sex workers. Just one female condom is used for every 200 male condoms used worldwide: in 2008, 35 million were available for distribution compared with six to nine billion male condoms.1

Campaigners at the 2010 International AIDS Conference in Vienna commented that, despite studies from as early as 1997 showing acceptability rates of 96% in men and women, it was still regarded with unease.2 “The female condom has been available for 15 years and for 15 years it has been joked about,” commented Lucie van Mens of the pressure group Universal Access to Female Condoms (see www.condoms4all.org). In 2004, Population Services International sold two million female condoms through its social marketing campaign, whereas it sold 867 million male condoms.

Nonetheless, the female condom is still the only female-controlled barrier method that has been proven to reduce sexually transmitted infections, and in the current absence of any other methods of proven efficacy, manufacturers, researchers and prevention advocates continue to promote this potentially extremely effective intervention tool and develop new versions that will gain more acceptability.

There are signs that in some populations of women in both low- and higher-income countries, female condom use is slowly gaining wider currency, especially since the second-generation FC2 female condom started to be licensed in various countries from 2005 onward. The number of female condoms distributed has tripled since 2005 and since the FC2 was finally licensed by the US Food and Drug Administration (FDA) in 2009, four years after it was introduced, there have been a number of promotion campaigns targeting women, especially from the African-American community, in cities such as New York, Chicago and Washington DC. It may not be too late for this technology to achieve wider popularity.


  1. Female Health Company New York City introduces second-generation female condom; less-expensive FC2 will help city expand female condom access. Media release, 16 November 2009
  2. AFP It works, but female condom neglected in anti-AIDS battle. AFP, 20 July 2009
This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap